James P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.
James P. Stevenson, MD
Advertisement
Articles by James P. Stevenson, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
2
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
3
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
4
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
5